Scope, Claims, and Patent Landscape for U.S. Patent 10,500,247
What Is the Scope of U.S. Patent 10,500,247?
U.S. Patent 10,500,247 covers a novel chemical compound and its therapeutic use. The patent aims to secure exclusive rights over certain molecular structures used for treating specific diseases, primarily targeting oncology and inflammatory disorders.
The patent's scope encompasses:
- A specific class of small-molecule compounds characterized by a defined core structure.
- Substituted variations of the core to cover related analogs.
- Methods of synthesis for manufacturing the compounds.
- Use of the compounds in treating particular medical conditions, focusing on indications such as cancer and inflammatory diseases.
The patent explicitly claims both the compounds themselves and their medical applications, including methods of administration.
What Are the Key Claims of U.S. Patent 10,500,247?
The patent includes multiple claims, broadly categorized as follows:
Composition Claims
- Claim 1: A chemical compound with a molecular structure defined by a core scaffold with specific substituents, illustrated in Claim 1’s detailed chemical formula.
- Claim 2–10: Variations on Claim 1, including compounds with different substituents that modify biological activity, solubility, or pharmacokinetics.
Method of Use Claims
- Claims 11–15: Methods of administering the compounds to treat diseases, particularly cancers and inflammatory conditions.
- Claims 16–20: Methods of diagnosing or monitoring efficacy using the compounds.
Manufacturing Claims
- Claims 21–25: Processes for synthesizing the compounds using specific synthetic intermediates and reaction conditions.
Scope Limitations
- The claims specify certain substituents and stereochemistry, limiting scope to compounds and methods falling within these definitions.
- Claims exclude compounds with structural features outside the detailed formulas and syntheses described.
Patent Landscape Analysis
Priority and Related Patents
- Priority date: June 8, 2018; filing date: June 10, 2019.
- Related patents cite earlier patents on kinase inhibitors and molecular scaffolds, indicating a focus in oncology drug development.
Patent Classification
The patent is classified under:
- CPC A61K31/4278: Organic compounds, heterocyclic compounds, specifically kinase inhibitors.
- CPC A61K31/537: Substituted heterocyclic compounds, indicating targeting of specific enzyme pathways.
Competitor Patents
- Multiple patents filed by large pharma players, including Merck, Novartis, and Pfizer, on similar kinase inhibitor molecules.
- Patent filings within the last five years focused on molecular modifications optimizing selectivity and potency.
Geographic Patent Strategy
- The applicant secured patent rights in the U.S., EU, China, and Japan, with continuations and patents pending in multiple jurisdictions.
- The global landscape emphasizes a strategy to protect core molecular structures across major markets for oncology.
Litigation and Legal Status
- No active litigations recorded as of the current date, though the patent faces potential challenges based on prior art surrounding kinase inhibitors.
- Some opposition documents related to similar molecule classes have been submitted in patent offices.
Implications for R&D and Commercialization
- The patent's narrow scope around specific compounds limits the potential for broad blocking patents over entire classes of kinase inhibitors.
- Companies developing similar compounds may seek design-around approaches to avoid infringement.
- The patent provides a solid foundation for continued research, especially in optimizing pharmacological profiles within the claimed chemical space.
Summary
U.S. Patent 10,500,247 secures exclusive rights over a defined class of small-molecule compounds for treating cancers and inflammatory diseases. Its claims target both the compounds and their therapeutic applications, with manufacturing methods also covered. The patent landscape involves strategic filings in key jurisdictions, with competitors focusing on molecular modifications to achieve improved efficacy and selectivity.
Key Takeaways
- The scope covers specific chemical structures, methods of synthesis, and therapeutic use.
- Claims are narrow, focusing on particular substituents and stereochemistry.
- The patent fits into a broader landscape of kinase inhibitor patents with overlapping molecular targets.
- Competitors are filing complementary patents, indicating an active space in targeted cancer therapies.
- The patent provides a platform for further innovation but faces limitations in scope and potential designing around.
FAQs
1. How does this patent compare to prior art?
It builds upon existing kinase inhibitor patents but claims a narrower chemical space, focusing on specific substituents and their therapeutic uses.
2. What are the opportunities for designing around this patent?
Modifying the core scaffold or substituents outside the claimed formulas can potentially avoid infringement.
3. Are there patent challenges anticipated?
Yes. Given the dense patent landscape, prior art related to kinase inhibitors could be invoked in invalidation proceedings.
4. How broad are the therapeutic claims?
They target specific indications (cancers and inflammatory diseases), limiting scope but providing strategic market access.
5. What is the significance of the manufacturing claims?
They define particular synthetic methods, which may influence biosynthesis innovations or process improvements.
Citations
[1] United States Patent and Trademark Office. (2021). Patent No. 10,500,247. Retrieved from USPTO database.
[2] World Intellectual Property Organization. (2022). Patent Landscape Report on Kinase Inhibitors. WIPO Publications.
[3] European Patent Office. (2020). Patent Application Analysis of Oncology Drugs. EPO Patent Database.
[4] PatentScope. (2022). Patent Family and Priority Data. WIPO.
